Novo Nordisk reported DKK118.72B in Debt for its fiscal quarter ending in March of 2025.





Debt Change Date
Bausch Health Companies USD 20.85B 191M Dec/2025
Bristol-Myers Squibb USD 47.14B 3.9B Dec/2025
Eli Lilly USD 42.5B 3.6M Dec/2025
GlaxoSmithKline GBP 19.06B 1.34B Mar/2026
Merck USD 49.34B 7.97B Dec/2025
Novartis USD 47B 11.62B Mar/2026
Novo Nordisk DKK 118.72B 61.75B Mar/2025
Novo Nordisk DKK 118.72B 15.94B Mar/2025
Pacira USD 367.66M 4.53M Mar/2026
Sanofi EUR 20.33B 1.43B Dec/2025
Supernus Pharmaceuticals USD 40.98M 1.23M Dec/2025